Based on this, the drug regulator has cleared the company to begin enrollment in the vaccines' planned Phase 3 trial. Novavax (NVAX) will be working with the clinical trial investigators and other ...

Maryland-based Novavax said it had enrolled the first participants in a phase 1/2 clinical trial of its coronavirus vaccine candidate. The vaccine, NVX-CoV2373, is a stable, prefusion protein ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

The purpose of the OWS grant was to enable Novavax to: ...complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. "Novavax is ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Novavax is expected to post a loss of $0.67 per share ...

Novavax anticipates being able to provide more clarity and information on potential next steps by Q2 2025, including if additional clinical work would be needed to achieve registration for these ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...